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Background: A low ratio of eicosapentaenoic acid (EPA)/arachidonic acid (AA) is considered a risk factor for
cardiovascular disease. Smoking is also a risk factor for cardiovascular disease even in an elderly population. This
study investigated the relationship between EPA/AA ratio and smoking status among elderly patients with type 2
diabetes mellitus (T2DM).
Findings: A total of 188 elderly patients with T2DM (men/women, 114/74; mean age, 65.0 ± 7.5 years) were studied
in terms of their smoking status, diabetic conditions, and blood data, including EPA and AA. Current smokers
showed a lower EPA/AA ratio than non-smokers (current smokers: 0.29, n = 49; non-smokers: 0.39, n = 139,
p < 0.01). This relationship remained significant after adjusting for multiple variables.
Conclusions: Smoking may affect the EPA/AA ratio among elderly patients with T2DM, suggesting a possible
mechanism of cardiovascular disease development and indicating the importance of smoking secession in
such patients.
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Cardiovascular disease (CVD) is a crucial pathology and
target for preventative action in patients with diabetes
mellitus (DM) [1]. The eicosapentaenoic acid (EPA)/
arachidonic acid (AA) ratio in blood is considered a
promising marker of myocardial infarction and cardiac
death [2-4] with a high EPA/AA ratio predicting a low
CVD risk [2,3].
Smoking is a major risk factor for CVD in DM [5-8],
the adverse effects of which on the cardiovascular system
can accumulate in elderly patients. Thus, in preventing
CVD events, the cessation of smoking in patients aged
over 50 years is considered to be equally as important as
in younger patients [9]. The association between EPA/AA
ratio and smoking status, especially in elderly patients
with type 2 DM (T2DM) has yet to be investigated, and
such information would be useful in clinical practice. The* Correspondence: kokada@jichi.ac.jp
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elderly patients with T2DM [9].
Methods
A total of 188 patients aged over 50 years, diagnosed with
T2DM (men/women, 114/74; mean age, 65.0 ± 7.5 years)
and not taking medications containing EPA and AA were
examined. Patients were excluded who had a history of
CVD event (s), a recent acute illness, systemic inflamma-
tory disease, severe nephropathy (i.e., stage 3 to 5), liver
dysfunction, or type 1 DM. The study was approved by
the Jichi Medical University Ethical Committee.
Hypertension was determined as systolic blood pressure
of ≥ 140 mmHg, diastolic blood pressure ≥90 mmHg, and/
or anti-hypertensive drug use [10]. Nephropathy was de-
fined by a urinary albumin-to-creatinine ratio of ≥ 30 mg/g
creatinine [11]. Fasting blood samples were collected at
our outpatient clinic in order to measure the levels of the
following parameters: glucose, hemoglobin A1c (HbA1c),
total cholesterol, triglyceride, high-density lipoprotein
(HDL) cholesterol, EPA, docosahexaenoic acid (DHA),
and AA.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Tosoh, Tokyo, Japan) was used to measure HbA1c. Serum
samples were collected in a heparinized poly-tube, lipids
were extracted by Folch’s procedure, and fatty acids (trico-
sanoic acid (C23:0) was used as an internal standard) were
methylated with boron trifluoride and methanol. EPA,
DHA, and AA levels in methylated fatty acids were ana-
lyzed by gas chromatography (GC-2010; Shimadzu, Kyoto,
Japan) with a capillary column (TC-70; GL Sciences Inc.,
Tokyo, Japan). Smoking habits were confirmed via self-
reporting.
Differences between current smokers and non-smokers
were analyzed using the t-test and Chi-square test. A
multivariable-adjusted analysis on the association be-
tween EPA/AA ratio and smoking status was performed
using a general linear model (SPSS software, SPSS Inc.,
IL, USA). Parameters with skewed distributions were log-
transformed in all analyses. A p-value of < 0.05 was con-
sidered to be significant.
Results
Current smokers were significantly younger in age, with a
greater proportion of males than non-smokers (Table 1).
They also exhibited a higher percentage of hypertension
and neuropathy, a higher level of HbA1c, and a lowerTable 1 Clinical characteristics
Parameters All (n = 188) Non-smoke
Age, years 65.0 ± 7.5 65.9
Gender, men/women 114/74 71
Body mass index, kg/m2 25.5 ± 4.3 25.6
Hypertension, n (%) 134 (71%) 93 (
Glucose, mg/dL 137 ± 47 138
Hemoglobin A1c, % 7.3 ± 0.9 7.2
Insulin therapy, n (%) 55 (29%) 41 (
Retinopathy, n (%) 78 (41%) 56 (
Neuropathy, n (%) 107 (57%) 73 (
Nephropathy, n (%) 76 (40%) 53 (
LDL-cholesterol, mg/dL 92 ± 28 92
HDL-cholesterol, mg/dL 61 ± 16 63
Triglycerides, mg/dL 107 (73-148) 101 (6
Statin therapy, n (%) 83 (44%) 63 (
AA, μg/mL 173 (143-210) 170 (1
DHA, μg/mL 128 (109-176) 129 (1
DHA/AA ratio 0.78 (0.60-1.04) 0.81 (0
EPA, μg/mL 61 (42-101) 62 (4
EPA/AA ratio 0.37 (0.23-0.63) 0.39 (0
LDL: low-density lipoprotein, HDL: high-density lipoprotein, AA: arachidonic acid, EP
Data are the means ± standard deviations, medians (interquartile ranges) or numbe
*p < 0.05, ** p < 0.01: comparison between current smokers and non-smokers (t-tesHDL cholesterol level than non-smokers. There were no
significant differences in AA, DHA, and EPA levels be-
tween current smokers and non-smokers.
Of note, a significantly lower EPA/AA ratio was demon-
strated in current smokers than in non-smokers (median,
0.29 versus 0.39, p < 0.01). Weak correlations between EPA/
AA ratio and other variables (age, gender, BMI, hyperten-
sion, HbA1c, insulin therapy, complications, lipids, and
statin therapy) were observed for the entire population
(p > 0.05 in all, data not shown). A significant difference
in the EPA/AA ratio between groups (p = 0.02) remained
after adjusting for multiple variables (age, gender, BMI,
hypertension, HbA1c, insulin therapy, complications, lipids,
and statin therapy).
Discussion
This study found current smokers to have a lower EPA/AA
ratio than non-smokers among elderly patients with T2DM,
indicating that smoking can detrimentally affect the EPA/
AA balance in such patients. Considering that the EPA/AA
ratio is a predictor of CVD events in patients with DM
[2,3] and smoking cessation is an achievable and effective
option for preventing CVD [7,8], the findings in this study
strongly support the importance of smoking cessation in the
management of CVD among elderly patients with T2DM.rs (n = 139) Current smokers (n = 49) P
± 7.4 62.4 ± 7.3 <0.01**
/68 43/6 <0.01**
± 4.4 25.2 ± 3.8 0.59
67%) 41 (84%) 0.03*
± 49 135 ± 40 0.64
± 0.9 7.6 ± 1.0 0.03*
29%) 14 (29%) 0.90
40%) 22 (45%) 0.57
53%) 34 (69%) 0.04*
38%) 23 (47%) 0.28
± 27 91 ± 33 0.87
± 16 56 ± 16 <0.01**
7-148) 121 (84-153) 0.05
45%) 20 (41%) 0.59
41-207) 180 (150-232) 0.31
11-176) 128 (98-177) 0.15
.62-1.07) 0.71 (0.55-1.00) 0.06
3-109) 56 (34-92) 0.06
.24-0.65) 0.29 (0.18-0.46) <0.01**
A: eicosapentaenoic acid, DHA: docosahexaenoic acid.
rs (%).
t or Chi-square test).
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http://www.dmsjournal.com/content/6/1/85Smoking results in various oxidants that are capable of
producing free radicals and lipid peroxidation [12]. Pa-
tients with T2DM are especially known to have high levels
of these oxidants [13]. Polyunsaturated fatty acids, particu-
larly omega-3 acid ethyl esters, undergo oxidation, leading
to a reduction in EPA in the presence of oxidants [14-16].
A previous report has indicated that AA levels in smokers
(mean age, 50 years) are decreased [17], which is inconsist-
ent with the findings of our study; however, another report
indicated that AA in smokers are not decreased [18]. Of
note, the metabolism of AA is not always parallel to that
of EPA [19-21], and compared to EPA, smoking has been
shown to delay the conversion rate of AA to eicosanoids
[22]. These findings may support an impairment of EPA/
AA balance, namely, a decrease in the EPA/AA ratio, ob-
served among smokers in our study. Our results should
be further analyzed using additional markers, such as oxi-
dative stress markers, in order to clarify the underlying
mechanisms.
Similar to EPA, DHA is also an omega-3 polyunsatur-
ated fatty acid. The pathological mechanism underlying
the difference between EPA and DHA is unclear. However,
clinical studies have reported that lower levels of EPA, but
not DHA, were significantly associated with all-cause mor-
tality [23], and that there was no clear association between
the DHA/AA ratio and cardiovascular risk [24]. The re-
sults of our study may be in line with these studies [23,24].
Some reports have shown that smoking worsens blood
pressure [25], glycemic control [26], and neuropathic con-
ditions [27,28]. Similar findings were observed in our study.
However, from the results of our adjusted analyses, these
variables do not seem to have a major influence on the as-
sociation between smoking status and EPA/AA ratio.
This study has certain limitations. This was a cross-
sectional study; thus, further intervention studies are re-
quired. Although we saw a significant difference in the as-
sociation between smoking status and EPA/AA ratio, the
small patient number might present a problem in terms of
a lower statistical power; thus, a larger-scale study is re-
quired. Additionally, as there is no information regarding
dietary fish consumption and the dose and duration of
smoking (e.g., the Brinkman index), and type of cigarette
were not investigated in detail, these must be included
into future work.
In summary, the present study suggests that current
smoking status and a low EPA/AA ratio may enhance
CVD risk in elderly patients with T2DM. Considering an
individual’s smoking status coupled with EPA/AA ratio
may be important in the management of T2DM, espe-
cially in the elderly. Further studies are expected.Abbreviations
CVD: Cardiovascular disease; DM: Diabetes mellitus; T2DM: Type 2
diabetes mellitus; EPA: Eicosapentaenoic acid; AA: Arachidonic acid;DHA: Docosahexaenoic acid; HbA1c: Hemoglobin A1c; HDL: High-density
lipoprotein.
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